Applied Dna Sciences (NASDAQ:BNBX – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.57) EPS for the quarter, FiscalAI reports. Applied Dna Sciences had a negative net margin of 1,647.25% and a negative return on equity of 349.95%. The business had revenue of $0.61 million during the quarter.
Applied Dna Sciences Stock Performance
Shares of BNBX traded down $0.01 during trading hours on Thursday, hitting $0.14. The stock had a trading volume of 137,847 shares, compared to its average volume of 487,344. Applied Dna Sciences has a 12-month low of $0.07 and a 12-month high of $7.15. The company has a market capitalization of $1.02 million, a price-to-earnings ratio of -0.00 and a beta of 0.60. The stock has a fifty day simple moving average of $0.28.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Applied Dna Sciences in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Applied Dna Sciences currently has a consensus rating of “Sell”.
About Applied Dna Sciences
Applied DNA Sciences is a U.S.-based biotechnology company that develops and commercializes molecular-level solutions for product authentication, supply chain security and forensic identification. The company’s technologies apply unique DNA markers and laboratory testing methods to tag, track and verify the authenticity of goods and materials, with the goal of combating counterfeiting, diversion and fraud across complex supply chains.
Central to Applied DNA’s offering is a suite of proprietary DNA-based markers and associated assays that can be incorporated into inks, fibers, coatings and other substrates to create tamper-evident, forensic-grade identifiers.
See Also
- Five stocks we like better than Applied Dna Sciences
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Applied Dna Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Dna Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
